TRPA1 agonists(Transient receptor potential cation channel subfamily A member 1 agonists), TRPM8 agonists(Transient receptor potential cation channel subfamily M member 8 agonists)

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic DiseasesRespiratory Diseases+ [1]

Active Indication

BronchitisSinusitisDiagnostic agents

Inactive Indication

Adenomatous Polyposis ColiCastration-Resistant Prostatic CancerGastric adenoma+ [2]

Originator Organization-

Active Organization-

Inactive Organization

Covance Pharmaceutical Research & Development (Beijing) Co.

Sandoz International GmbH

Nihon Pharmaceutical Co., Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC10H20O

InChIKeyNOOLISFMXDJSKH-WYVCTLLJSA-N

CAS Registry89-78-1

Clinical Trials associated with Menthol

NCT05932745 / Not yet recruitingNot ApplicableIIT

Examining Appeal and Addiction Potential of Novel E-cigarette Constituents Among Adults

This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.

Start Date01 Nov 2024

Sponsor / Collaborator

Yale University

[+1]

NCT05932693 / RecruitingNot ApplicableIIT

Examine the Effects of Novel E-cigarette Constituents and Determining Appropriate Concentrations Among Adults

This pilot sensory experiment will examine cooling from comparable concentrations of WS-3 and menthol to determine appropriate concentrations to use in the main study.

Start Date03 Sep 2024

Sponsor / Collaborator

Yale University

[+1]

NCT06444594 / Not yet recruitingEarly Phase 1IIT

Transient Receptor Potential Channels in Human Skin

Neurovascular signaling in the skin associated with stimulation of the transient receptor potential (TRP) channels. These channels are stimulated by both temperature and naturally occurring bioactive agents found in mint, chili peppers, garlic, etc. The aim of the study is to examine how topically applied TRP channel agonists including menthol, capsaicin and camphor impact neurovascular responses in the skin.

Start Date15 Jun 2024

Sponsor / Collaborator

The Pennsylvania State University

100 Clinical Results associated with Menthol

100 Translational Medicine associated with Menthol

100 Patents (Medical) associated with Menthol

2,779

Literatures (Medical) associated with Menthol

01 Dec 2024·European Journal of Pharmaceutics and Biopharmaceutics

Comparing effects of terpene-based deep eutectic solvent and solid microneedles on skin permeation of drugs with varying lipophilicity

Article

Author: Rades, Thomas ; Czyrski, Grzegorz S. ; Czyrski, Grzegorz S ; Frese Hjort, Mikkel K ; Heinz, Andrea ; Frese Hjort, Mikkel K.

Transdermal delivery of therapeutic molecules is often hindered by the properties of the skin, with the stratum corneum serving as the primary permeation barrier. To overcome this barrier, the integrity of the stratum corneum can be modified by chemical permeation enhancers, such as deep eutectic solvents (DESs), or by mechanically impairing the skin with microneedles (MNs). However, a systematic comparison between these strategies is currently lacking. Hence, this study examined the potential of DESs and MNs to promote the permeation and retention of drugs with varying lipophilicities - specifically, the hydrophilic drug metronidazole (logP ∼ 0), the moderately lipophilic drug lidocaine (logP ∼ 2.3), and the highly lipophilic drug clotrimazole (logP ∼ 5). A mixture of menthol and thymol was selected as a model terpene-based DES and delivery vehicle, while a DermaPen equipped with solid MNs was used to mechanically impair the skin. Permeation rates of model drugs applied to the skin with either DES, MNs, or both were compared to the rates determined for the drugs applied in control vehicles. Both strategies were found to compromise the skin barrier function, but their permeation-enhancing effect was dependent on the lipophilicity of tested model drug. The DES was most effective for the hydrophilic drug metronidazole, while the MNs were more effective in increasing the permeation of the highly lipophilic drug clotrimazole. For the moderately lipophilic drug lidocaine, neither the DES nor microneedles increased its permeation rate, as the drug permeated through the skin well on its own. Notably, the combination of both enhancement strategies did not result in significantly better permeation rates of the drugs compared to the individual approaches. In conclusion, both the terpene-based DES and solid MNs are effective strategies to enhance drug permeation through the skin, but our results suggest that the choice of strategy should be dictated by the drug's lipophilicity. Moreover, from a permeation-enhancing perspective, there is no benefit in combining these two strategies.

01 Dec 2024·Molecular Biology Reports

Menthol as an effective inhibitor of quorum sensing and biofilm formation in Candida albicans and Candida glabrata by targeting the transcriptional repressor TUP1

Article

Author: Khodavandi, Alireza ; Khodavandi, Pouria ; Soogh, Maryam Miri ; Alizadeh, Fahimeh ; Nouripour-Sisakht, Sadegh

BACKGROUNDMenthol, a natural quorum sensing molecule, is derived from the Mentha species. Combating pathogenicity by inactivating quorum sensing is an emerging approach. Therefore, our objective was to investigate anti-quorum sensing and anti-biofilm potentials of menthol in Candida albicans and Candida glabrata.METHODSThe antifungal properties of menthol were evaluated using a broth microdilution assay and a time-kill assay, and its effects on quorum sensing-mediated virulence factors, cellular reactive oxygen species (ROS), and biofilm formation were tested by evaluating TUP1 expression levels in both C. albicans and C. glabrata.RESULTSQuorum sensing-mediated virulence factors and biofilm formation were inhibited by menthol in both C. albicans and C. glabrata. Furthermore, coinciding with elevated ROS levels, mRNAs of the quorum sensing-related gene TUP1 were upregulated in both C. albicans and C. glabrata.CONCLUSIONSThis study highlights the anti-quorum sensing potential of menthol through the inhibition of quorum sensing-mediated virulence factors, ROS generation, and biofilm development by targeting TUP1, which could have potential in the treatment of Candida infections.

01 Dec 2024·Toxicology Reports

E-cigarette flavoring chemicals and vehicles adversely impact the functions of pigmented human retinal ARPE-19 cells

Article

Author: Goenka, Shilpi

Electronic cigarettes (ECs) have been shown to adversely impact the human eye's retinal pigment epithelium (RPE). Flavored e-liquids induced cytotoxicity in unpigmented human ARPE-19 cells independent of nicotine's presence in my previous study. In the current study, human ARPE-19 cells pigmented by sepia melanin were employed to examine the effects of four flavoring chemicals, vanillin, menthol, furanone, and cinnamaldehyde, and EC vehicles propylene glycol (PG)/vegetable glycerin (VG) ratios (0:100, 80:20, 100:0 % v/v), on metabolic activity, membrane integrity, oxidative stress, and wound healing capacity of these cells. Results demonstrate that cinnamaldehyde was the most cytotoxic flavoring, and all vehicles showed marked cytotoxicity at the highest concentration of 10 %. All four flavorings elicited a significant production of reactive oxygen species (ROS), while the three vehicles did not impact ROS levels. Vanillin significantly (p < 0.05) suppressed wound healing, while furanone and cinnamaldehyde had no effects, although menthol promoted wound healing at the lowest concentration. Moreover, the vehicles with two ratios of 0:100 PG/VG and 80:20 PG/VG suppressed wound healing. Together, these results suggest that vanillin and VG-containing vehicles exert the greatest adverse effects on ARPE-19 cells. These findings underscore the potential harm that exposure to ECs can cause to the human retina.

News (Medical) associated with Menthol

05 Nov 2024

·www.drugs.com

Banning Menthol Cigarettes Might Drive Smokers to Quit-Smoking Therapies

TUESDAY, Nov. 5, 2024 -- Banning menthol cigarettes could help convince smokers quit the habit, a new study finds. People who prefer menthol cigarettes would rather buy nicotine gum or other nicotine replacement therapies than switch to traditional tobacco cigarettes, researchers reported recently in the journal Drug and Alcohol Dependence . In addition, menthol cigarette smokers were less likely to use e-cigarettes as a substitute if menthol vaping products are also restricted, researchers found. “I think the most important conclusion from this study is that we can improve health outcomes by emphasizing policies that reduce sales of flavored products and increase accessibility of nicotine replacement therapies,” said researcher Roberta Freitas-Lemos , an assistant professor at the Virginia Tech Fralin Biomedical Research Institute. More than 9 million adults -- about 32% of all smokers -- use menthol cigarettes, researchers said in background notes. Menthol makes smoking easier by reducing the harshness of cigarette smoke and cooling the throat. The Biden Administration has come under fire for delaying a proposed U.S. Food and Drug Administration ban on menthol cigarettes. In a September hearing before Congress, FDA leaders said a menthol ban is still in the works. "It's a priority for us. We followed through rule-making processes and it's presently with the White House and it continues to be a priority for us," Brian King, director of the FDA's Center for Tobacco Products, told a House Energy and Commerce Committee hearing. For the new study, researchers analyzed data from 172 people who smoke cigarettes, including 76 who only smoke menthol cigarettes and 96 who smoke non-menthol cigarettes. They also looked at 91 who use multiple types of tobacco products. The smokers were asked to use an online account to buy tobacco and nicotine products, which included replacement therapies. When menthol cigarettes weren’t available, smokers who prefer menthol were less willing to buy other types of cigarettes. Instead, they turned to nicotine replacement products like patches or gum. The study also found higher demand for high-ventilation cigarettes, which feature filter holes for airflow that make the smoke less harsh. “Cigarettes with ventilation are milder and people think they are less harmful, but it is a false perception,” Freitas-Lemos said in a Virginia Tech news release. Bans of these products could help smokers choose to quit, the researchers concluded. “It could be that people who smoke ventilated cigarettes are more responsive to one ban than another,” Freitas-Lemos said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

24 Sep 2024

·www.prnewswire.com

Stop Itchy Skin in its Tracks

5 tips for relief from a board-certified dermatologist ROSEMONT, Ill., Sept. 24, 2024 /PRNewswire/ -- Itchy skin can be irritating, especially an itch that doesn't go away. There are many potential causes for itchy skin like common skin conditions such as eczema, shingles, hives, psoriasis, or bug bites, or it could be a sign of a contagious disease, like scabies or ringworm. While these causes could mean a visit to a board-certified dermatologist, there are options for self-care at home to provide itch relief. "Our first instinct is to scratch that pesky itch, but in reality, that could be making things worse by irritating your skin further," said Susan Massick, MD, FAAD, clinical associate professor of dermatology at The Ohio State University. "Everyone experiences itchy skin from time to time, but relief can be possible by following a few easy steps at home." To help soothe itchy skin, Dr. Massick and the American Academy of Dermatology recommend following these tips: Apply a cool, damp washcloth to itchy skin for about 5-10 minutes, or until the itch goes away. Take a warm colloidal oatmeal bath. This can soothe your skin, especially if the cause of your itch is chickenpox, hives, poison ivy, or sunburn. Apply a "fragrance-free" moisturizer when your skin is still damp after bathing or whenever it itches. Soaps, detergents, and other products should also be "fragrance-free" as fragrance can irritate the skin. If your moisturizer doesn't relieve the itch, apply a cooling agent, like menthol or calamine. You can also try an over-the-counter cream or gel that contains pramoxine, a topical pain reliever. Sometimes keeping these in the refrigerator also helps. Wear loose-fitting, cotton clothes. These help you stay cool and won't irritate your skin, like wool and other rough-feeling fabrics can. Avoid extreme temperature changes, as these can make itch worse. Keep your house cool during the summer and use a humidifier and avoid high heat in the winter. "If you do not find relief after trying these at-home tips, or if you notice changes to your skin, such as redness, swelling, rash, bumps, or sores, a board-certified dermatologist can diagnose the underlying condition," said Dr. Massick. "Often, itching can have more than one cause, and together we can work toward a treatment plan that offers the best results, healthier skin, and, ultimately, symptom relief." These tips are demonstrated in "How to relieve itchy skin," a video posted to the AAD website and YouTube channel. This video is part of the AAD's "Your Dermatologist Knows" series, which offers tips people can use to properly care for their skin, hair, and nails. To manage itchy skin and learn more tips, partner with a board-certified dermatologist. To find a board-certified dermatologist in your area, visit aad.org/findaderm. More Information Itchy Skin Resource Center 10 Reasons Your Skin Itches and How to Get Relief AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Sep 2024

·www.prnewswire.com

IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients

CRANBURY, N.J., Sept. 17, 2024 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced the completion of patient recruitment for its Phase 1/2 clinical trial evaluating IVW-1001, a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, for the treatment of signs and symptoms of dry eye disease. The company anticipates reporting topline data in the first quarter of 2025. Advancing Toward Promising Results "We are thrilled to have reached this significant milestone in our clinical development program for IVW-1001," said Houman Hemmati, MD, PhD, Chief Medical Advisor at IVIEW Therapeutics Inc. "Completing patient enrollment brings us one step closer to potentially offering a new therapeutic option for individuals suffering from dry eye disease. We are eagerly awaiting the trial results and remain optimistic about the potential impact on patient care." A Step Forward in Innovative Ophthalmic Treatments Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc., commented, "The completion of patient recruitment ahead of schedule is a testament to the dedication of our clinical team and the interest from the ophthalmic community. IVW-1001's novel mechanism of TRPM8 activation and its innovative delivery through an ophthalmic eyelid wipe could offer a differentiated treatment for dry eye disease worldwide. We look forward to sharing our findings as soon as they are available." About IVIEW Therapeutics Inc. IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focusing on innovative ophthalmic therapeutics. Driven by the pursuit of cutting-edge science, we aim to develop differentiated products that fulfill unmet medical needs. We invest in novel mechanisms of action and advanced drug delivery technology platforms to bring forward assets with potentially superior target product profiles. Our innovative portfolio of small molecules and gene therapy assets covers dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. Located in Cranbury, New Jersey, IVIEW operates a state-of-the-art 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit our website at . SOURCE IVIEW Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

100 Deals associated with Menthol

External Link

KEGG	Wiki	ATC	Drug Bank
D04918	Menthol	R05X	DB14123

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchitis	-	-	-
Sinusitis	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diagnostic agents	Phase 1	CN	-	26 Dec 2018
Diagnostic agents	Preclinical	CN	Shandong Bestcomm Pharmaceutical Co., Ltd.	26 Dec 2018
Pharyngitis	Preclinical	RU	Sandoz International GmbH	22 Feb 2017
Adenomatous Polyposis Coli	Preclinical	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011
Castration-Resistant Prostatic Cancer	Preclinical	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011
Gastric adenoma	Preclinical	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011
Stomach Cancer	Preclinical	JP	Nihon Pharmaceutical Co., Ltd.	01 Sep 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01855607 (CTgov)	Phase 2	Colonic Cancer \| Breast Cancer \| Peripheral Nervous System Diseases \| Neuropathy	12	placebo+menthol	fpaazfvkzg(sliqrcokao) = fwcjyxpiue jkaitrfpgw (strmufsmfb, yzxcfkzihw - sihdsyrmoy) View more	-	11 Jul 2024
ATS2023	Not Applicable	Respiratory Insufficiency	-	Electronic Cigarette Menthol Flavoring (Menthol-flavored ECs)	njiliadrvv(duqyyysijn) = reduced quwyjbdpae (ydramksgub ) View more	-	21 May 2023
				Electronic Cigarette Menthol Flavoring (Non-menthol-flavored ECs)
Pubmed	Not Applicable	-	234	Nicotine e-cigarettes with menthol	njotanyrbb(ccuehykttx) = ggaqiyqigu lprayrzjgx (gvgihvqgvr )	-	20 Oct 2021
				Nicotine e-cigarettes without menthol	njotanyrbb(ccuehykttx) = hxhhgmeeju lprayrzjgx (gvgihvqgvr )
NCT03095508 (CTgov)	Phase 3	Pharyngitis	229	Angal S, topical spray [Menthol] (Angal S (Arm A))	lmowtmrjiy(uxddxqrbgk) = svxrrplejt kimtuizxvu (araepzzfcz, zkvanyiwfm - hjaxjqndsw) View more	-	21 Mar 2019
				ANTI-ANGIN® FORMULA, topical metered spray (ANTI-ANGIN® FORMULA (Arm B))	lmowtmrjiy(uxddxqrbgk) = rdrkseaixd kimtuizxvu (araepzzfcz, amxtqrixfy - linylxmouj) View more
NCT02102100 (CTgov)	Not Applicable	Nicotine Dependence	57	nicotine+menthol (Menthol-Preferring Smokers)	humayprtqg(pwogvvdpps) = chikpipjma btyrtsqqsw (awntcujjxk, sogyyqcsix - skglkeomjo) View more	-	20 Feb 2019
				nicotine+menthol (Non-Menthol Preferring Smokers)	humayprtqg(pwogvvdpps) = yrornvvdnw btyrtsqqsw (awntcujjxk, hhkraicppk - lbquvqpqrd) View more
NCT02100670 (CTgov)	Phase 3	Pain \| Ankle Injuries	385	3% menthol (3% Menthol)	tlexetwmen(qcyoodktio) = pzyrjytmev qagnrjhjeg (ixhtitjzxs, fumxudpzro - fjqxzuqswi) View more	-	12 Jan 2018
				1% diclofenac sodium plus 3% menthol (1% Diclofenac Sodium Plus 3% Menthol)	ctysslmlgf(ieneaiajmo) = vpxwbndvrd tdicqkfiot (ossavbpypg, gmcdovaiaz - rjvyxyudcp) View more
UEGW2014	Not Applicable	Dyspepsia	-	Menthol (Patients with dyspepsia symptoms)	wvzbqpefkj(eofdnkychq) = qrzzhsltnj ejsazugnzb (emmobwqick )	-	01 Oct 2014
				Menthol (Healthy subjects without abdominal symptoms)	wvzbqpefkj(eofdnkychq) = kmppivfgjc ejsazugnzb (emmobwqick )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis